SCHEMBL63506

SCHEMBL63506

O=C(Oc1c(C(=O)NCc2ccc(F)cc2)nc2n(c1=O)CC1CCC2C1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.40
KCNH2 Q12809 1/20 0.40
CYP2C9 P11712 1/20 0.40
PTGER4 P35408 1/20 0.37
LMNA P02545 1/20 0.37
OPRM1 P35372 1/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
OGFRL1 Q5TC84 1/20 0.37
ALDH1A1 P00352 1/20 0.36
THRB P10828 1/20 0.36
GAA P10253 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HMGCR P04035 1/20 0.36
TP53 P04637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13691554 0.82 KCNH2 (0.55) SMN1; SMN2KCNH2CYP2C9ALDH1A1GAA
SCHEMBL61799 0.77 KCNH2 (0.56) SMN1; SMN2KCNH2CYP2C9ALDH1A1GAA
SCHEMBL14173536 0.75 SMN1; SMN2 (0.51) SMN1; SMN2PTGER4LMNAALDH1A1L3MBTL1
SCHEMBL62329 0.72 KCNH2 (0.51) SMN1; SMN2KCNH2CYP2C9ALDH1A1GAA
SCHEMBL63435 0.72 KCNH2 (0.46) SMN1; SMN2KCNH2CYP2C9LMNAALDH1A1
SCHEMBL51927 0.72 LMNA (0.46) SMN1; SMN2KCNH2CYP2C9LMNAALDH1A1
SCHEMBL52622 0.71 KCNH2 (0.52) SMN1; SMN2KCNH2CYP2C9ALDH1A1GAA
SCHEMBL63257 0.69 KCNH2 (0.53) SMN1; SMN2KCNH2CYP2C9LMNAALDH1A1
SCHEMBL63436 0.69 KCNH2 (0.56) SMN1; SMN2KCNH2CYP2C9LMNAGAA
SCHEMBL62276 0.69 CYP2C9 (0.50) SMN1; SMN2KCNH2CYP2C9LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG SMN1; SMN2 4431/4885KCNH2 3969/4885CYP2C9 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.